572 related articles for article (PubMed ID: 15001164)
1. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
2. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
[TBL] [Abstract][Full Text] [Related]
5. Active-specific immunization against melanoma: is the problem at the receiving end?
Monsurrò V; Wang E; Panelli MC; Nagorsen D; Jin P; Katia Z; Smith K; Ngalame Y; Even J; Marincola FM
Semin Cancer Biol; 2003 Dec; 13(6):473-80. PubMed ID: 15001166
[TBL] [Abstract][Full Text] [Related]
6. [Advances in cellular immunotherapy for malignant melanoma].
López M; Escobar A; Alfaro J; Fodor M; Larrondo M; Ferrada C; Salazar-Onfray F
Rev Med Chil; 2004 Sep; 132(9):1115-26. PubMed ID: 15543770
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
9. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations.
Tuettenberg A; Schmitt E; Knop J; Jonuleit H
J Dtsch Dermatol Ges; 2007 Mar; 5(3):190-6. PubMed ID: 17338793
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
12. Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors.
Bundell CS; Jackaman C; Suhrbier A; Robinson BW; Nelson DJ
Cancer Immunol Immunother; 2006 Aug; 55(8):933-47. PubMed ID: 16283304
[TBL] [Abstract][Full Text] [Related]
13. Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells.
Glazyrin AL; Kan-Mitchell J; Mitchell ML
Cancer Immunol Immunother; 2003 Mar; 52(3):171-8. PubMed ID: 12649746
[TBL] [Abstract][Full Text] [Related]
14. Cytokine-based therapy and biochemotherapy for advanced melanoma.
Atkins MB
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2353s-2358s. PubMed ID: 16609058
[TBL] [Abstract][Full Text] [Related]
15. In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients.
De Vries IJ; Bernsen MR; van Geloof WL; Scharenborg NM; Lesterhuis WJ; Rombout PD; Van Muijen GN; Figdor CG; Punt CJ; Ruiter DJ; Adema GJ
Cancer Immunol Immunother; 2007 Oct; 56(10):1667-76. PubMed ID: 17440724
[TBL] [Abstract][Full Text] [Related]
16. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
17. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
18. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
19. Melanoma cancer vaccines and anti-tumor T cell responses.
Vujanovic L; Butterfield LH
J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
[TBL] [Abstract][Full Text] [Related]
20. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients.
Trakatelli M; Toungouz M; Blocklet D; Dodoo Y; Gordower L; Laporte M; Vereecken P; Sales F; Mortier L; Mazouz N; Lambermont M; Goldman S; Coulie P; Goldman M; Velu T
Cancer Immunol Immunother; 2006 Apr; 55(4):469-74. PubMed ID: 16133111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]